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14 Abstract MicroRNAs (miRNAs) are small non-protein-
15 coding RNAs that regulate expression of a wide variety of
16 genes including those involved in cancer development. Here,
17 we investigate the role of miR-143 in breast cancer. In this
18 study, we showed that miR-143 was frequent ly
19 downregulated in 80 % of breast carcinoma tissues compared
20 to their adjacent noncancerous tissues. Ectopic expression of
21 miR-143 inhibited proliferation and soft agar colony
22 formation of breast cancer cells and also downregulated
23 DNA methyltransferase 3A (DNMT3A) expression on both
24 mRNA and protein levels.Q2 Restoration of miR-143 expression
25 in breast cancer cells reduces PTEN hypermethylation and
26 increases TNFRSF10C methylation. DNMT3A was
27 demonstrated to be a direct target of miR-143 by luciferase
28 reporter assay. Furthermore, miR-143 expression was
29 observed to be inversely correlated with DNMT3A mRNA
30 and protein expression in breast cancer tissues. Our findings
31 suggest that miR-143 regulates DNMT3A in breast cancer
32 cells. These findings elucidated a tumor-suppressive role of
33 miR-143 in epigenetic aberration of breast cancer, providing a
34 potential development of miRNA-based treatment for breast
35 cancer.
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54Breast cancer is one of the three most commonly diagnosed
55cancers among women, accounting for about 30 % of
56patients [1]. In the past decades, despite the dedication of
57research and resources to the development of biomarkers for
58diagnosis and prognosis, unpredictable response and
59development of resistance to adjuvant therapy remain major
60challenges in breast cancer management. Although
61mammography diagnosis for breast cancer is the currently
62used screening tool, the cost incurred and expertise required
63for mammogram has hampered wide application of this
64procedure. On the other hand, alternative methods such as
65ultrasound screening has very operator-dependent sensitivity,
66and tumor markers such as CA15.3 and carcinoembryonic
67antigen (CEA) are also nonspecific and has limited
68sensitivity and specificity [2]. Thus, there is still a pressing
69need to elucidate novel mechanism of breast cancer
70development so as to develop a cost-effective and accurate
71screening method for this cancer.
72Recently, the emergence of small non-protein-coding
73RNAs, microRNAs (miRNAs), playing important roles in
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74 oncogenesis, has opened new opportunities for early cancer
75 diagnosis [3, 4]. Evidence suggests that miRNA expression
76 profiles can cluster similar tumor types together more
77 accurately than the expression profiles of protein-coding
78 mRNA genes [5]. Furthermore, miRNA expression signatures
79 have been used to predict prognosis [6, 7]. Importantly,
80 expression of some miRNAs correlated with the molecular
81 subtypes and with two major features of breast cancer (grade
82 and ER status) [8]. Therefore, miRNA has a great potential to
83 be a novel biomarker for breast cancer and holds promising
84 potential for individualizing patients' treatment regimens [9],
85 although, as yet, there is still limited knowledge on the exact
86 mRNA target of the deregulated miRNA in breast cancer.
87 Research shows that each miRNA could target up to 200
88 mRNA transcripts, and a single mRNA could have multiple
89 miRNA binding sites [10]. This finding indicates that there is
90 a great demand to further investigate on the mRNA targets and
91 understand the functional role of these differentially expressed
92 miRNAs, so as to elucidate their potential as therapeutic
93 agents or targets.
94 In this study, we investigated the functional role of miR-
95 143 in breast cancer. MiR-143, located on chromosome 5q33,
96 is a miRNA found to be deregulated in colon cancer [11] and
97 bladder cancer [12]. It is previously demonstrated that miR-
98 143 targets on DNA methyltransferase 3A (DNMT3A)
99 mRNA [11 ] . DNMT3A i s t h e membe r o f t h e
100 methyltransferase family. DNMT3A and 3B are responsible
101 for de novo methylation in the genome [13], while DNMT1 is
102 responsible for maintaining methylation in the genome. The
103 expression level of DNMT3A is high in early embryonic stage
104 and downregulated in differentiated cells; maintaining high
105 expression of DNMT3A in embryonic cells will inhibit cell
106 differentiation [13].
107 Until now, the role of DNMT3A in cancer is less studied
108 than DNMT3B. There are reports showing that DNMT3A
109 deficiency promotes tumor growth and progression [13].
110Q4 The downregulation of miR-143 in tumor can lead to the
111 overexpression of DNMT3A, which in turn causes
112 hypermethylation and silencing of the tumor suppressor genes
113 and contributes to tumorigenesis.
114 One of the most researched tumor suppressor genes is the
115 phosphatase and tensin homolog (PTEN) which acts as a
116 negative regulator of PI3K/AKT signaling pathway [14].Q5 A
117 high proportion of human cancers have a mutated form of
118 PTEN or abnormal PTEN expression, and this attributed to
119 40 % of breast cancer [15]. Mutation and inactivation of
120 PTEN gene lead to hyperactivation of PI3K/AKT pathway,
121 which causes cell cycle deregulation and suppression of
122 apoptosis [16]. Evidences showed that breast cancer patients
123 with defective PTEN have poor prognosis and high grade
124 tumor [15].
125 We aimed to show that miR-143 and DNMT3A are both
126 deregulated in breast cancer and prove that overexpression of
127DNMT3A has caused a change in methylation status of PTEN
128and TNFRSF10C which contributed to tumorigenesis. These
129results help to understand the molecular mechanism of how
130miR-143 promotes cancer progression.
131Materials and methods
132Cell lines and tissue samples
133Five human breast cancer cell lines including MCF-7, MD-
134MB-231, MD-MB-468, T47D, and SK-BR-3 and two colon
135cancer cell lines HT-29 and SW480 (American Type Culture
136Collection, Manassas, VA) were cultured at 37 °C in 10 %
137CO2 atmosphere and maintained routinely in Dulbecco's
138modified Eagle's Medium (DMEM) supplemented with
13910 % fetal bovine serum and 2 mM of L -glutamine
140(Invitrogen, Carlsbad, CA). A total of 20 pairs of primary
141breast tumors and noncancerous tissue counterparts were
142collected. All samples were collected from patients who
143underwent surgical resection of tumors. Informed consent
144has been obtained from each patient. This project was
145approved by the Institutional Review Board of the University
146of Hong Kong.
147Real-time quantitative PCR
148Total RNA containing small RNAwas extracted from tissues
149and cell lines by TRIzol reagent (Invitrogen) according to the
150instructions of the manufacturer. SYBR Green real-time
151qPCR assay for miRNA expression was used as previously
152described [11, 17]. In brief, 100 ng of total RNA containing
153miRNAwas polyadenylated and reverse-transcribed to cDNA
154by using miScript Reverse Transcription Kit (Qiagen)
155according to the manufacturer's instructions. Real-time qPCR
156was performed using miScript SYBR Green PCR Kit
157(Qiagen) in ABI PRISM 7900 HT System (Applied
158Biosystems, Foster City, CA). The miR-143-specific forward
159primer sequence was 5′-TGAGATGAAGCACTGTAGCTC-
1603′ and was designed based on the miRNA sequences obtained
161from the miRBase database. Human U6 snRNAwas used for
162normalization. For DNMT3A mRNA qPCR, total RNA was
163reverse-transcribed to cDNA by using miScript Reverse
164Transcription Kit (Qiagen) according to the manufacturer's
165instructions. Gene-specific primers for DNMT3A gene were
166used as previously described [17]. The mRNA expression was
167normalized to β-actin. ΔCt was calculated by subtracting the
168Ct values of U6 or β-actin from the Ct values of the gene of
169interest.ΔΔCt was then calculated by subtracting theΔCt of
170the control from the ΔCt of cancer sample. Fold change of
171gene was calculated by the equation 2−ΔΔCt.
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172 Ectopic miR-143 expression
173 Ectopic expression of miR-143 in breast cancer cells (MD-
174 MB-231 and MCF7) was achieved by transfection with
175 mature miR-143 mimic (Qiagen). Cells were plated in culture
176 dishes or 6/96-well plates for 24 h and transfected with 1 nM
177 of mimic with HiPerFect Transfection Reagent (Qiagen) for
178 24 h. Precursor control (Ambion, Austin, TX) was used as
179 negative control. Cells were then subjected to further assays or
180 for RNA/protein extraction.
181 Cell proliferation assay
182 Cell proliferation was measured by 3-(4,5-dimethylthiazol-2-
183 yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
184 tetrazolium (MTT) assay (Promega Corporation, Madison,
185 WI). MB-231 (2×106) and MCF-7 (5×106) cells were
186 seeded in a 96-well plate for 24 h, transfected with 1 nM
187 miR-143 mimic (Qiagen) and HiPerFect Transfection
188 Reagent (Qiagen) for 24 h and further grown in normal
189 medium for 3 days. Thereafter, cells were incubated in
190 0.1 mg/ml MTT at 37 °C for 3 h and lysed in dimethyl
191 sulfoxide (DMSO) at room temperature for 30 min. The
192 absorbance in each well was measured at 580 nm by a
193 microplate reader.
194 Anchorage-independent colony formation assay
195 Soft agar plates were prepared in 24-well plates with a bottom
196 layer of 0.6 % Noble agar in serum-free DMEM. Cells were
197 trypsinized, and 500 cells were seeded onto the bottom layer
198 after being mixed with 0.3 % Noble agar in DMEM
199 supplemented with 10 % fetal calf serum. Plates were
200 incubated at a 37 °C incubator for 3 weeks. The number of
201 colonies was counted after stained with 0.05 % crystal violet
202 for 1 h and washed extensively with phosphate-buffered saline
203 (PBS).
204 Western blot analysis
205 Cells were lyzed in Lammeli's lysis buffer, resolved in SDS-
206 PAGE minigel, and transferred onto Immobilon-P membrane
207 (Millipore, Billerica, MA). Membranes were probed with 1:1,
208 000 diluted primary antibodies against DNMT3A (Cell
209 Signaling) at room temperature for 2 h, washed extensively
210 with 0.1 % Tween-20 in PBS, and incubated with secondary
211 antibodies conjugated with horse-radish peroxidase (1:10,000
212 dilution). The signals were visualized with enhanced
213 chemiluminescence (Amersham Life Science Inc.,
214 Buckinghamshire, UK).
215Luciferase activity assay
216DNMT3A 3′UTR containing an intact miR-143 recognition
217sequence was amplified, and the PCR product (199 bp) was
218subcloned into pGL3 basic vector (Promega, Madison, WI)
219immediately downstream of luciferase gene, as described
220previously [11]. A pGL3 construct containing DNMT3A 3′
221UTR with point mutations in seed sequence was also
222synthesized using Site-Directed Mutagenesis Kit (Stratagene,
223La Jolla, CA) according to the manufacturer's instructions.
224Cells were co-transfected with 800 ng of pGL3 constructs
225with or without miR-143 precursor for 24 h. Each sample
226was co-transfected with 0.05 μg pRL-CMV plasmid
227expressing Renilla luciferase to monitor the transfection
228efficiency (Promega, Madison, WI). Luciferase activity assay
229was performed 24 h after transfection using Dual-Luciferase
230Reporter Assay System (Promega). Relative luciferase
231activity was normalized with Renilla luciferase activity.
232Methylation-sensitive PCR
233Genomic DNA from cell lines with or without miR-143-mimic
234transfection used for methylation analysis was extracted by
235DNeasy Mini Kit (Qiagen) according to the user manual.
236Methyl-Profiler DNA Methylation qPCR Primer Assays (SA
237Biosciences) was used to determine the methylation status of
238the promoter in different genes. In brief, 250 μg of genomic
239DNA was used for enzyme digestion by using a Methyl-
240Profiler Enzyme Kit. For each sample, mock digestion (Mo),
241methylation-sensitive digestion (Ms), methylation-dependent
242digestion (Md), and double digestion (Msd) was performed by
243adding different combinations of enzyme according to the
244manufacturer's protocol and was placed in 37 °C heating block
245for 6 h, followed by heat inactivation at 65 °C for 20 min.
246SYBR Green-based qPCR was performed with a panel of 26
247breast cancer methylated gene promoters (MeAH-011C, SA
248Biosciences), on PRISM 7900 HT. Ct was obtained after
249qPCR, and the relative amount of methylation was calculated
250by first determining the relative amount of DNA resistance to
251enzyme digestion (Cr): 2−ΔCt(Msd−Mo). Q6Then the degree of
252methylation of each gene promoter can be calculated as follows:
253(1) amount of hypermethylation (CHM): (2
−ΔCt(Ms−Mo)−Cr)/(1−
254Cr); (2) amount of hypomethylation (CUM): (2
−ΔCt(Md−Mo)−Cr)/
255(1−Cr); and (3) amount of intermediately methylated DNA: 1−
256CHM−CUM.
257Statistical analysis
258Paired t test was used in the expression comparison of miR-
259143 between paired breast tumor and adjacent noncancerous
260tissues. Two-sided Student's t test was used to analyze MTT
261assay, anchorage-independent soft agar assay, and luciferase
262reporter assay. Data are expressed as the mean ± SD from at
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263 least three independent experiments. All P values are two-
264 sided, and a value of less than 0.05 was considered statistically
265 significant. All statistical calculations were performed by the
266 SPSS software (version 13.0, Chicago, IL, USA).
267 Results
268 MiR-143 is downregulated in breast tumor and human breast
269 cancer cell lines
270 MiR-143 has been reported to be downregulated in other
271 cancers like bladder cancer and colon cancer. To examine the
272 expression levels of miR-143 in breast cancer, 20 pairs of breast
273 tumor with adjacent normal tissue and five breast cancer cell
274 lines were quantified by real-time PCR. The expression level of
275 miR-143 in all the five breast cancer cell lines (MCF7, MB-
276 231, MB-468, T47D, and SK-BR-3) was lower than that of
277 noncancerous breast tissue (Fig. 1a). For patient samples, low
278 expression of miR-143 was found in tumor compared with the
279 adjacent normal tissues (P <0.05, Wilcoxon test; Fig. 1b).
280 The effect of miR-143 on cell growth and DNMT3A
281 expression
282 Low expression levels of miR-143 in breast cancer cells
283 suggest that miR-143 has a role in breast cancer
284 carcinogenesis.Q8 To prove this, enforced expression of miR-
285 143 on cell growth in MB-231 and T47D breast cancer cells
286 was tested by MTT assay and colony formation assay. After
287 transfection with miR-143, bothMB-231 and T47D showed a
288 significant decrease in growth rate (22 % decrease for MB-
289 231 and 30 % decrease for T47D; Fig. 2a, b). Colony
290 formation assay was performed to determine the degree of
291 invasiveness in different cell lines after miR-143 mimic
292transfection. Figure 2c showed the overexpression of miR-
293143 after transfection with miR-143 mimic when compared to
294control the precursor. The increased miR-143 expression
295significantly reduced anchorage-dependent growth in both
296cell lines as shown in Fig. 2c (all P <0.05; Mann–Whitney
297test), confirming that miR-143 also affects the malignant
298transformation phenotypes. These results suggested that
299miR-143 has a role in suppressing tumor cell growth. We then
300examined the correlation between miR-143 and DNMT3A.
301Our results indicated that restored expression of miR-143
302leads to decreased expressions of DNMT3A mRNA
303(Fig. 2d) and protein (Fig. 2e) in both cell lines, which suggest
304a potential regulatory role of miR-143 on DNMT3A.
305Direct interaction between DNMT3A and miR-143
306To confirm that DNMT3A is the direct target of miR-143,
307luciferase assay was performed. In short, wild-type (WT) or
308mutated (MUT) 3′UTR of DNMT3A (11) was subcloned into
309downstream of the firefly luciferase reporter and co-
310transfected with miR-143 precursor or precursor control into
311both MB-231 and T47D breast cancer cell lines. In the
312presence of miR-143, the relative luciferase activity of breast
313cancer cell lines with WT construct was significantly reduced
314(Fig. 3b; P <0.05 for MB-231, P <0.01 for T47D; Mann–
315Whitney test). While no significant suppressive effect by
316miR-143 was found in cells transfected with the MUT
317construct, this suggested a direct and specific interaction of
318miR-143 on DNMT3A 3′UTR in breast cancer cells.
319Expression relationship between miR-143 and DNMT3A
320in breast tumor tissue
321To confirm the relationship between miR-143 and DNMT3A,
322we assessed the expression of miR-143 and DNMT3A protein
323in breast tumor tissues from ten patients. As shown in Fig. 4a,
324there is no correlation between miR-143 and DNMT3A
325mRNA expression. However, DNMT3A protein levels were
326inversely correlated with miR-143 (r =−0.61, P <0.05;
327Spearman's correlation; Fig. 4b).
328Methylation status of PTEN
329To examine the effect of DNMT3A downregulation on
330methylation status of PTEN gene, we performed the
331methylation-sensitive PCR. As shown in Fig. 5, ectopic
332expression of miR-143 in MB-231 reduced hypermethylated
333DNA on PTEN gene promoter from 50 to 2.3 %, while that of
334unmethylated DNA raised from 50 to 97.7 %. In addition,
335hypermethylated TNFRSF10C reduced from 50 to 25 %,
336whereas unmethylated TNFRSF10C reduced from 50 to
3370.8 %, and that of intermediate methylated DNA increased





















Fig. 1Q7 Downregulated miR-143
expression in both primary breast
tumor tissues and breast cancer
cell lines. a Relative miR-143
expression in breast cancer cell
lines was much lower than the
noncancerous breast tissue (N1).
b Relative miR-143 expression
between tumor and their paired
adjacent nontumor tissues from
20 patients by real-time qPCR.
Expression of miR-143 (Log10
scale at Y-axis) was normalized to
U6. Statistical difference was
analyzed by Wilcoxon test,
P<0.05
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340 Since the discovery of miRNAs, the differential expression
341 pattern of miRNAs in various cancers has been reported;
342 however, the functional roles of individual miRNAs towards
343 cellular transformation and tumorigenesis continue to be
344 actively studied. Increasing evidence showed that miRNAs
345might be involved in tumorigenesis by regulating oncogenes
346or tumor suppressor genes. A recent report showed that
347miRNA and epigenetic methylations are interconnected and
348contributed to tumorigenesis [18, 19]. In this study, we
349showed that miRNA can affect methylation through altering





































































































































bFig. 2 Functional effect of
ectopic miR-143 expression in
MB-231 and T47D cells. Ectopic
miR-143 expression reduced
growth rate of both a MB-231
and b T47D cell lines assessed by
MTT (Mann–Whitney test, *P <
0.05, *P <0.001). c Anchorage-
independent growth of cancer
cells, examined by soft agar
colony formation assay, was
reduced. Cells were plated in
0.3 % Noble agar for 3 weeks.
The number of colonies was
counted after being stained with
0.05 % crystal violet (Mann–
Whitney test, *P<0.05).
Overexpression of miR-143
reduced both d mRNA and e
protein expression of DNMT3A.
Cells were transfected with miR-
143 precursor or control precursor
for 24 h and then lysed for RNA
or protein extraction. DNMT3A
mRNAwas detected by real-time
qPCR (Mann–Whitney test,
*P<0.05), and the protein
expression was detected by
Western blotting with anti-
DNMT3A antibody. β-actin was
used as a loading control
Tumor Biol.















352 It has been reported previously that miR-143 is deregulated
353 in colorectal cancer [20], prostate cancer [21], B cell
354 lymphoma [22], etc. In this study, we demonstrated that
355 miR-143 is downregulated not only in breast cancer cell lines
356 but also in primary breast tumors. The frequent
357 downregulation ofmiR-143 suggests a tumor-suppressive role
358 in breast cancer. We verified this by the enforced expression of
359miR-143 in breast cancer cells, resulting in a suppression of
360malignant transformation.
361To further understand the tumor-suppressive role of miR-
362143, in silico target prediction (PicTar and TargetScan 5) is
363used for target prediction. Despite a large number of predicted
364potential targets for miR-143, only a limited amount was
365verified. There were reports showing that miR-143 acted on
366extracellular signal-regulated kinase 5 (Erk5) which in turn
367affects the mitogen-activated protein kinase (MAPK)
368pathways [21]. MAPK is an important pathway for
369oncogenesis, as it involves in cell proliferation, differentiation,
370and migration [23]. Apart from Erk5, DNMT3A is also a
371predicted target of miR-143.
372DNMT3A together with DNMT1 and DNMT3B are
373catalytically active DNMTs responsible for genome
374methylation [24]. DNMT1 is a maintenance DNA
375methyltransferase for retaining methylation pattern, with
376inefficient de novo methylation ability. DNMT3A and
377DNMT3B are de novomethyltransferase with different targets
378[25]. Increasing evidence showed that these DNMTs work
379together to maintain a normal methylation pattern, and
380deregulation of either one could promote malignancies [26].
381In this study, we showed that there is a correlation between
382miR-143 and DNMT3A in breast cancer. Enforced expression
383of miR-143 suppressed tumor transformation and DNMT3A
384mRNA and protein. Site-directed mutation on the 3′UTR of
385DNMT3A revealed the presence of specific binding site of
386miR-143. An inverse correlation of miR-143 and DNMT3A
387expression in human breast samples further consolidated miR-
388143 negatively regulated DNMT3A.
389Genome-wide hypomethylation is common in cancer
390genomes which causes genome instability [27]; whereas
391site-specific hypermethylation in the promoter region of the
392tumor suppressor gene causing gene silencing is often




























Fig. 3 DNMT3A is the direct target of miRNA-143. a The wild-type
(WT ) and mutant (MUT ) DNMT3A 3′UTR, with or without point
mutations in the seed sequence. b Ectopic miR-143 expression inhibited
WT, but not MUT DNMT3A 3′UTR reporter activity in MB-231 and
T47D cells. Cells were co-transfected with miR-143 precursor and either
WTorMUTDNMT3A 3′UTR reporter construct. Luciferase activity assay
was performed at 24 h post-transfection (Mann–Whitney test, *P<0.05,
**P<0.01)
Fig. 4 Expression level of miR-143 and DNMT3A were tested in ten
tumor samples. a Expression relationship between miR-143 and
DNMT3A mRNA. b Scatter plot of the fold changes of miR-143 and


























Fig. 5 Effect of ectopic miR-143 expression on PTEN and TNFRSF10C
promoter methylation status in MB-231 cells. HM , hypermethylated;
UM, unmethylated; IM, intermediate methylated
Tumor Biol.















394 due to mutations in methyltransferase gene or imbalanced
395 methyltransferase biogenesis. MiRNAs modulate
396 posttranscription repression and maintain the balance of gene
397 expression level in the cells [29]. We demonstrated that miR-
398 143 targeted on DNMT3A gene and caused transcriptional
399 repression. LowmiR-143 expression increased the expression
400 of DNMT3A enzymewhich caused hypermethylation in other
401 tumor-suppressing genes.
402 PTEN has long been known for its tumor-suppressive
403 property; inactivation of PTEN could lead to various cancers
404 [30]. Homozygous mutation is often found in familial and
405 sporadic cancer. In breast cancer, reduction or complete
406 absence of PTEN protein is found in about 40 % of the cases,
407 mostly due to loss of heterozygosity (LOH), rarely somatic
408 mutation [31]. The lowmutation rate and high LOH suggested
409 that epigenetic modification is responsible for the lost or
410 reduced expression of PTEN protein. Many reports showed
411 that promoter CpG hypermethylation is the reason for PTEN
412 expression silencing.Methylation of PTENwas also shown to
413 correlate with estrogen and progesterone receptor level which
414 is highly related to the invasiveness of breast cancer, or even
415 drug resistance [16, 32]. Recent research showed that PTEN
416 expression is methylation-dependent and is preferentially
417 methylated by DNMT3A [33]. By depleting DNMT3A,
418 PTEN expression could be resumed due to demethylation of
419 the CpG islands in the promoter region. Therefore, depletion
420 of DNMT3A could exhibit antiproliferative effects.
421 Being the preferential targets of DNMT3A [33], changes in
422 methylation level of PTEN genes depend on the DNMT3A
423 level inside the cells. Our results showed for the first time that in
424 restoration of miR-143, the methylation status of PTEN has
425 been changed. With lowered expression of DNMT3A after
426 miR-143 transfection, percentage of hypermethylated DNA in
427 PTEN promoter drastically reduced, while that of unmethylated
428 DNA increased. This clearly showed that miR-143 indirectly
429 control the PTEN expression level through DNMT3A.
430 The tumor necrosis factor receptor superfamily member
431 10C (TNFRSF10C) located on 8p22-p21 encodes a protein
432 in the TNF receptor superfamily [34]. It has an extracellular
433Q9 TNF-related apoptosis-inducing ligand (TRAIL)-binding
434 domain and a transmembrane domain, but lacks cytoplasmic
435 death domain. This antagonistic receptor protects cell from
436 TRAIL-induced apoptosis. Deletion of TNFRSF10C locus
437 has been reported in lung cancer [35] and prostate cancer
438 [36], while methylation of TNFRSF10C has been reported
439 in lung cancer, pancreatic cancer, and breast cancer [37]. A
440 recent study reported that the higher frequency of
441 TNFPSF10C methylation resulted in tumor cell growth,
442 suggesting a tumor-suppressive role in carcinogenesis [38].
443 In our study, we are the first to find a decrease in
444 hypermethylation of TNFGSF10C after being transfected
445 with miR-143 mimic. This may suggest a potential role of
446 DNMT3A in the methylation of TNFRSF10C expression.
447In conclusion, we found that miR-143 was frequently
448downregulated in breast cancer, which might be a potential
449tumor suppressor. The direct targeting of miR-143 on
450DNMT3A suggested for the first time that miR-143 took part
451in the regulation of DNA methylation and caused PTEN and
452TNFRSF10C methylation. These novel findings provided a
453new insight into the relationship of miRNA and methylation,
454which may provide a new direction for the development of
455miRNA-based target treatment.
456
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